Coronavirus (Covid-19) Vaccine Latest Update: Novavax begins injecting vaccine candidate into people in Australia; human trials of ICMR's Covid-19 vaccine might begin in six months With Covid-19 infecting more than 5.5 million and killing 346,326 people across the world, according to Johns Hopkins University tracker, the US is planning a massive testing effort involving more than 100,000 volunteers and half a dozen of the most promising vaccine candidates to deliver a safe and effective jab by the end of 2020, Reuters reported.
Meanwhile, what buttresses the fact of India’s growing role in development for a cure for Covid-19, French Ambassador Emmanuel Lenain has said the country had an important hand to play in the mass production of vaccines.
For Covid-19, there are over 100 vaccines being developed across the world now, some from scratch, some from existing molecules developed for other diseases. Most of the experimental vaccines in progress aim to train the immune system to recognize the “spike” protein that studs the coronavirus’ outer surface, priming the body to react if it was exposed to the real virus. There are at least 10 vaccines in human trials, according to the World Health Organization (WHO).
COVID19
Migration to be theme of next Bihar polls: Kushwaha
Gowda skips quarantine after flight to Bengaluru, says he has immunity
How the states handled domestic flights on Day
Homecoronavirus outbreak
Coronavirus (Covid-19) vaccine latest update: Novavax starts tests in Australia; ICMR vaccine human trials in six months
Coronavirus (Covid-19) Vaccine Latest Update: Novavax begins injecting vaccine candidate into people in Australia; human trials of ICMR's Covid-19 vaccine might begin in six months
Coronavirus (Covid-19) Vaccine Latest Update: There are at least 10 vaccines in human trials, according to the World Health Organization (WHO). (Illustration)
RELATED NEWS
Delhi: At least 183 recovered in last 24 hrs, total Covid-19 cases rise to 14,465
Congress not a key decision maker in Maharashtra government, says Rahul Gandhi
No home quarantine for asymptomatic passengers arriving in Delhi
With Covid-19 infecting more than 5.5 million and killing 346,326 people across the world, according to Johns Hopkins University tracker, the US is planning a massive testing effort involving more than 100,000 volunteers and half a dozen of the most promising vaccine candidates to deliver a safe and effective jab by the end of 2020, Reuters reported.
Meanwhile, what buttresses the fact of India’s growing role in development for a cure for Covid-19, French Ambassador Emmanuel Lenain has said the country had an important hand to play in the mass production of vaccines.
For Covid-19, there are over 100 vaccines being developed across the world now, some from scratch, some from existing molecules developed for other diseases. Most of the experimental vaccines in progress aim to train the immune system to recognize the “spike” protein that studs the coronavirus’ outer surface, priming the body to react if it was exposed to the real virus. There are at least 10 vaccines in human trials, according to the World Health Organization (WHO).
Coronavirus (Covid-19) vaccine latest updates:
💉 US biotechnology company Novavax has become the latest to announce that it has started human trials of its NVX-CoV2373 vaccine for Covid-19 in Australia, AP reported. Novavax will inject 131 volunteers in the first phase of the trial, the company’s research chief Dr Gregory Glenn said.
“The trial began with six volunteers being injected with the potential vaccine in Melbourne on Tuesday,” said Paul Griffin, infectious disease expert with Australian collaborator Nucleus Network.
The results of the first phase of clinical trials in Melbourne and Brisbane are expected to be known in July following which thousands of candidates in several countries would then become involved in a second phase.
Animal testing suggested the recombinant vaccine is effective in low doses. Novavax is planning to manufacture at least 100 million doses this year and 1.5 billion in 2021.
Novavax uses genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. Scientists extracted and purified the protein, and packaged it into virus-sized nanoparticles.
Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate
A pharmacist gives a woman the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19.
💉 Japanese biopharma venture AnGes Inc said it would begin clinical trials for its DNA vaccine in July, earlier than previously planned, according to a report in The Japan Times. The news saw shares jumping as much as 19 percent in Tokyo trading, taking its gaining streak to a fourth day.
In a statement, AnGes said animal trials of the vaccine it had been conducting with Osaka University since March had confirmed an increase in antibodies. “We will examine the results of the toxicity data and swiftly move forward to clinical trials,” AnGes said.
DNA vaccines are a type of vaccine that use genetic material from pathogens to produce antibodies by inducing an immune system response. While such a vaccine has yet to be approved for human use, the technology has been touted by experts as safe and one that can ease large-scale manufacturing.
If the effectiveness is proven, the vaccine may receive approval by the end of the year, Nikkei Asian Review said in a report.
💉 Coming to India, the Indian Council of Medical Research (ICMR) told news agency IANS that human trials of its Covid-19 vaccine might begin in six months. The ICMR and Bharat Biotech International Limited (BBIL) are jointly developing the vaccine.
“The virus strain isolated at the National Institute of Virology (NIV) laboratory in Pune will be used to develop the vaccine, and this strain has been successfully transferred to BBIL. It is expected that the human trials of the vaccine will begin in at least six months,” Dr Rajni Kant, Director Regional Medical Research Centre and Head at ICMR said.
ICMR and BBIL are working towards developing a killed virus vaccine that usually provides good immunogenicity. By entering the body, it will create antibody against the infection. Presently, while Zydus Cadila is working on two vaccines, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax are developing one vaccine each.
For more update click here to join in our website Worldtech:-👇👇
http://www.worldtechad.blogspot.com
Post a Comment